AbbVie stock fell 12% to about $204 recently, but JPMorgan views this as a buying opportunity, keeping an Overweight rating and $260 price target. Despite competitive pressure from Johnson & Johnson and a $744 million R&D charge lowering earnings guidance, key drugs Skyrizi and Rinvoq continue strong sales growth, driving optimism. AbbVie posted record 2025 revenues of $61.16 billion, with immunology and neuroscience segments growing significantly. The stock offers a 3.18% dividend yield and raised dividends recently, making it attractive for long-term investors if growth sustains and competition remains manageable.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
